Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G/A

MDxHealth SA

MDXHNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Jan 16, 2026Accepted Jan 16, 2026, 10:38 AM ESTFiling CIK 1124140Accession 0001124140-26-000003
Share

Structured filing — SCHEDULE 13G/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
MDxHealth SA
Company CIK
0001872529
Street
CAP Business Center
Street (continued)
Zone Industrielle des Hauts-Sarts
City
Herstal
State / country code
C9
Postal code
4040

Statement details

Amendment number
1
Security class
Ordinary shares, no par value
Event date
01/09/2026
Rule designation
Rule 13d-1(c)

Reporting person 1

Name
Genomic Health, Inc.
Citizenship / organization
DE
Reporting person type
CO
Aggregate amount owned
6,441,171.00
Percent of class
12.0
Sole voting power
6,441,171.00
Shared voting power
0.00
Sole dispositive power
6,441,171.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N
Comments
Row 11 is calculated based on 49,497,334 ordinary shares issued and outstanding as described in the Issuer's Registration Statement on Form F-3 filed with the U.S. Securities and Exchange Commission on December 29, 2025.

Reporting person 2

Name
Exact Sciences Corporation
Citizenship / organization
DE
Reporting person type
CO
Aggregate amount owned
6,441,171.00
Percent of class
12.0
Sole voting power
0.00
Shared voting power
6,441,171.00
Sole dispositive power
0.00
Shared dispositive power
6,441,171.00
Aggregate excludes certain shares
N
Comments
Row 11 is calculated based on 49,497,334 ordinary shares issued and outstanding as described in the Issuer's Registration Statement on Form F-3 filed with the U.S. Securities and Exchange Commission on December 29, 2025.

Item 1

Issuer

MDxHealth SA

Principal executive office address

CAP Business Center, Zone Industrielle des Hauts-Sarts, Herstal, C9, 4040

Item 2

Citizenship

(a) Genomic Health, Inc. - Delaware (b) Exact Sciences Corporation - Delaware

Filing person

(a) Genomic Health, Inc. (b) Exact Sciences Corporation

Principal business or residence address

(a) The business address of Genomic Health, Inc. is 5505 Endeavor Lane, Madison, WI 53719 (b) The business address of Exact Sciences Corporation is 5505 Endeavor Lane, Madison, WI 53719

Item 3

Not applicable indication

Y

Item 4

Percent of class

See responses to Item 11 on the attached cover pages.

Amount beneficially owned

As of the date hereof, Genomic Health, Inc. owns 2,441,171 Ordinary Shares and warrants/contractual rights to purchase an additional 4,000,000 Ordinary Shares of the Issuer. Genomic Health, Inc. is a wholly owned subsidiary of Exact Sciences Corporation. Exact Sciences Corporation, through the ownership described herein may be deemed to beneficially own the Ordinary Shares directly owned by Genomic Health, Inc.

Sole voting power

See responses to Item 5 on the attached cover pages.

Shared voting power

See responses to Item 6 on the attached cover pages.

Sole dispositive power

See responses to Item 7 on the attached cover pages.

Shared dispositive power

See responses to Item 8 on the attached cover pages.

Item 5

Not applicable indication

Y

Ownership of 5% or less

N

Item 6

Not applicable indication

Y

Item 7

Not applicable indication

Y

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Exhibits

See Exhibit 99.1 for Joint Filing Agreement, dated as of January 16, 2026, by and among the Reporting Persons

Signature 1

Reporting person
Genomic Health, Inc.
Signed
/s/ James Herriott
Title
James Herriott, Secretary
Date
01/16/2026

Signature 2

Reporting person
Exact Sciences Corporation
Signed
/s/ James Herriott
Title
James Herriott, Senior Vice President, General Counsel and Secretary
Date
01/16/2026

Filed exhibits

Company context

Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests, based on proprietary genomic, epigenomic, exosomal and other molecular technologies, assist physicians with the diagnosis and prognosis of prostate cancer and other urologic diseases. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

Current securities

Historical securities (1)

Recent company filings

  1. SCHEDULE 13G - filed by Rail-Splitter Capital Advisers LLC regarding MDxHealth SANov 16, 2026
  2. 6-K filingNov 12, 2026
  3. 6-K filingOct 30, 2026
  4. 6-K filingOct 16, 2026
  5. SCHEDULE 13D/A - filed by Bleichroeder LP regarding MDxHealth SAOct 15, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.